8-K: UroGen Pharma Reports Strong Q2 2026 Results, ZUSDURI Revenue Soars

UroGen Pharma announced robust second quarter 2026 financial results, highlighted by a 73% surge in ZUSDURI revenue to $50.4 million and significant progress in its drug development pipeline.

Summary

• UroGen Pharma reported total revenue of $72.5 million for the second quarter of 2026, a substantial increase from $24.2 million in the same period of 2025, primarily driven by the commercial launch of ZUSDURI.
• ZUSDURI generated $50.4 million in revenue, marking a 73% quarter-over-quarter growth, and has reached 1,444 activated sites of care with 452 unique prescribers.
• The company expects a new U.S. patent, once issued, to provide intellectual property protection for ZUSDURI and UGN-103 until July 2044.
• UGN-103 is on track for a New Drug Application (NDA) submission in Q3 2026, with potential FDA approval in 2027.
• UGN-501, an investigational oncolytic virus, is slated to begin a Phase 1 clinical trial in Q4 2026.
• JELMYTO revenue was $22.0 million for Q2 2026, and the company maintains its full-year guidance of $97 million to $101 million.
• The company reported a net loss of $14.4 million ($0.28 per share) for Q2 2026, an improvement from a net loss of $49.9 million ($1.05 per share) in Q2 2025.
• Cash, cash equivalents, and marketable securities stood at $108.0 million as of June 30, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, driven by strong revenue growth for ZUSDURI and promising pipeline advancements, despite an overall net loss.

Positives

• ZUSDURI revenue reached $50.4 million in Q2 2026, demonstrating a strong 73% quarter-over-quarter growth.
• The number of repeat ZUSDURI prescribers increased to approximately 45% of total prescribers, up from 40% in Q1 2026.
• A new U.S. patent allowance is expected to provide intellectual property protection for ZUSDURI and UGN-103 until July 2044.
• UGN-103 is progressing well, with an NDA submission planned for Q3 2026.
• UGN-501 has received FDA acceptance for its Investigational New Drug application and is set to begin Phase 1 trials in Q4 2026.
• JELMYTO revenue is on track to meet full-year guidance of $97 million to $101 million.
• Net loss significantly decreased to $14.4 million in Q2 2026 from $49.9 million in Q2 2025.
• Total revenue more than tripled year-over-year, reaching $72.5 million in Q2 2026.

Negatives

• The company reported a net loss of $14.4 million for the quarter.
• JELMYTO revenue decreased slightly to $22.0 million in Q2 2026 from $24.2 million in Q2 2025.
• Selling, General, and Administrative (SG&A) expenses increased to $48.4 million from $43.2 million year-over-year, attributed to ZUSDURI commercial activities.
• Total operating expenses increased to $65.8 million from $62.1 million year-over-year.
• Cash, cash equivalents, and marketable securities decreased to $108.0 million from $120.5 million at the end of 2025.
• Total shareholders' deficit widened to $132.4 million from $105.5 million at the end of 2025.

Risks

• Potential safety and other complications related to UroGen's products.
• Risks associated with protecting intellectual property, including the possibility that pending patent applications may not be successful.
• Challenges in maintaining regulatory approval for products.
• Complications associated with commercialization activities and labeling limitations.
• Competition in the urothelial cancer market.
• The scope, progress, and expansion of developing and commercializing products and product candidates.
• Market acceptance of products versus alternative therapies.
• The potential for payors to delay, limit, or deny coverage for ZUSDURI.

Future Outlook

The company anticipates continued growth driven by ZUSDURI, with pipeline advancements for UGN-103 and UGN-501 expected to contribute to long-term shareholder value. Full-year 2026 JELMYTO revenue is projected between $97 million and $101 million. Full-year 2026 operating expenses are now guided to be between $260 million and $270 million, reflecting increased investment in ZUSDURI commercial activities and pipeline development.

Management Comments

• "The second quarter marked another important step in establishing ZUSDURI as a foundational therapy for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer."
• "The continued increase in utilization, expanding adoption across community practices, and growing repeat use reinforce our confidence we are building a durable commercial franchise with blockbuster potential."
• "We believe this meaningfully enhances the long-term commercial opportunity for both products and further reinforces the sustainability of the franchise."
• "Combined with the life-cycle expansion of UGN-103 and initiation of clinical development for UGN-501, we believe we are exceptionally well positioned to build a durable growth company and create long-term shareholder value."

Industry Context

StockSavvy.ai notes that UroGen Pharma operates in the competitive oncology sector, specifically focusing on urothelial cancers. The strong performance of ZUSDURI and the advancement of its pipeline, particularly UGN-103, position the company to capitalize on unmet needs in bladder cancer treatment. The extended patent protection for ZUSDURI and UGN-103 is a significant positive in an industry where intellectual property is crucial for long-term commercial success.

Comparison to Industry Standards

• ZUSDURI's 73% quarter-over-quarter revenue growth is exceptionally strong for a commercial-stage pharmaceutical product, especially in the oncology space.
• The 64.5% duration of response (DOR) at 36 months for ZUSDURI in the ENVISION trial, among patients achieving complete response at three months, demonstrates competitive efficacy compared to other treatments for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
• UGN-103's 94.5% DOR at six months in the UTOPIA trial is comparable to ZUSDURI's performance in the ENVISION trial, suggesting consistent efficacy of the RTGel technology.
• The net loss of $14.4 million in Q2 2026, while still a loss, represents a significant improvement from the $49.9 million loss in Q2 2025, indicating progress towards profitability, which is a key benchmark for growth-stage biotech companies.

Legal Proceedings

• UroGen entered into a settlement and license agreement with Teva Pharmaceuticals to resolve patent litigation concerning a generic version of JELMYTO.

Stakeholder Impact

• Shareholders: Improved financial performance with significant revenue growth and reduced net loss, alongside positive pipeline developments, could lead to increased shareholder value.
• Patients: Continued availability and potential expansion of ZUSDURI and JELMYTO offer treatment options for urothelial cancers. Advancements in UGN-103 and UGN-501 promise future therapeutic innovations.
• Healthcare Providers: Growing adoption of ZUSDURI and positive clinical data reinforce its utility in clinical practice, potentially simplifying treatment protocols.
• Payors: Increased ZUSDURI utilization and strong clinical data may influence coverage decisions, though potential delays or limitations remain a risk.

Next Steps

• Submit New Drug Application (NDA) for UGN-103 in Q3 2026.
• Initiate Phase 1 clinical trial for UGN-501 in Q4 2026.
• Complete enrollment for the Phase 3 clinical trial of UGN-104 by the end of 2026.
• Initiate a Phase 3 trial for UGN-103 in high-risk NMIBC in the second half of 2026.
• Increase investment in ZUSDURI peer-to-peer promotional education and patient awareness initiatives.
• Accelerate start-up activities for the UGN-103 high-grade NMIBC trial and development activities of UGN-501 with RTGel.

Key Dates

Recommendation

The strong revenue growth of ZUSDURI, significant improvement in net loss, positive pipeline progress with key regulatory milestones approaching, and extended patent protection present a compelling investment case. The company is demonstrating effective commercial execution and robust R&D momentum, suggesting continued upward trajectory.

Keywords

ZUSDURI, bladder cancer, urothelial cancer, UGN-103, JELMYTO, mitomycin, oncology, biotech